Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO

Luxa Biotechnology will provide update on their clinical trial for retinal pigment epithelial stem cell (RPESC) technology for the treatment of dry age-related macular degeneration (AMD) at ARVO 2023. The panel session, evaluating the cell transplant for the treatment of dry AMD, will be held on April 24th at the ARVO exhibition hall.

RPESC-RPE-4W is derived from an adult retinal pigmented epithelium stem cell (RPESC) that produces retinal pigmented epithelium (RPE) cell progeny. The transplanted RPESC-RPE-4W has shown to maintain the function of RPE cells and support the overlying photoreceptor cells, resulting in sustained improvement in vision.

For more information about the session and to register, please visit https://emmes-20580327.hs-sites.com/reserve-your-spot 

Original articles

• https://markets.financialcontent.com/stocks/news/publisher/luxa%20biotechnology

• https://www.galvnews.com/news_ap/business/luxa-biotechnology-to-provide-update-on-clinical-trial-of-retinal-pigmented-epithelium-stem-cell-rpesc/article_280ffeff-d17f-5206-b094-199854c981ad.html?block_id=531919 

• https://www.wvnews.com/business/luxa-biotechnology-to-provide-update-on-clinical-trial-of-retinal-pigmented-epithelium-stem-cell-rpesc/article_b047c565-c445-5d11-aa07-ff9a2b508fb7.html

• https://www.businesswire.com/news/home/20230420005075/en/Luxa-Biotechnology-to-Provide-Update-on-Clinical-Trial-of-Retinal-Pigmented-Epithelium-Stem-Cell-RPESC-Technology-for-Treatment-of-Dry-Age-Related-Macular-Degeneration-in-Panel-Session-at-ARVO-2023

• https://finance.yahoo.com/news/luxa-biotechnology-clinical-trial-retinal-110000880.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMoWHLBSSjlRka-zPPHu7u2oAMtL4QuBAjB-BWpJcWs9upLo8HPsfk5EEnOpmFUH88cGC81lFD9ul8ERz6N1KxQrhr5XXT59qB-XjHQ5fMENB2AvFB6C1t0dWExgmardbYv69ou0KFFF4qeMahd75QHDjSKKsngrFrKTRXscsF1i

• https://www.qlifepro.com/press/20230420-20-97209/nj-luxa-biotechnology/

• https://www.ophthalmologytimes.com/view/arvo-live-luxa-biotechnology-gives-update-on-clinical-trial-of-rpesc-technology-for-dry-amd

• https://www.bloomberg.com/press-releases/2023-04-20/luxa-biotechnology-to-provide-update-on-clinical-trial-of-retinal-pigmented-epithelium-stem-cell-rpesc-technology-for